{
    "name": "apomorphine",
    "comment": "Rx",
    "other_names": [
        "Apokyn",
        "Kynmobi"
    ],
    "classes": [
        "Antiparkinson Agents",
        "Dopamine Agonists"
    ],
    "source": "https://reference.medscape.com/drug/apokyn-kynmobi-apomorphine-343040",
    "pregnancy": {
        "common": [
            "Adequate data on the developmental risk associated with use of apomorphine are not available in pregnant women",
            "In animal reproduction studies, apomorphine had adverse developmental effects in rats (increased neonatal deaths) and rabbits (increased incidence of malformation) when administered during pregnancy at clinically relevant doses; these doses were also associated with maternal toxicity"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Consider the developmental and health benefits of breastfeeding along with the motherâ€™s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity, including angioedema or anaphylaxis",
                "Sulfite/sulfur allergies (Apokyn contains sodium metabisulfite)",
                "Do not use 5-HT3 antagonists, including antiemetics (eg, granisetron, dolasetron, ondansetron, palonosetron) - risk of profound hypotension and loss of consciousness"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Subcutaneous use only; thrombus formation and pulmonary embolism have followed IV administration owing to crystallization of apomorphine",
                "Severe nausea and vomiting occurs at recommended doses; because of this, pretreat or treat with trimethobenzamide; trimethobenzamide reduces incidence of nausea and vomiting during first 4 weeks of therapy; patients treated with trimethobenzamide experience greater incidence of somnolence, dizziness and falls; benefit of treatment with trimethobenzamide must be balanced with risk for those adverse events, and treatment with trimethobenzamide should only be continued as long as necessary to control nausea and vomiting, which should generally be no longer than 2 months",
                "Closely monitor patients with mild and moderate hepatic impairment",
                "Falling asleep during activities of daily living and daytime somnolence may occur",
                "Oral mucosal irritaiton reported with SL product",
                "Syncope and hypotension/orthostatic hypotension may occur",
                "Falls may occur, or increase owing to underlying postural instability, possible autonomic instability, and syncope caused by low blood pressure",
                "May cause hallucinations and psychotic-like behavior",
                "May cause dyskinesia or exacerbate pre-existing dyskinesia (reported with SC administration)",
                "May cause problems with impulse control and impulsive behaviors; consider dose reduction or discontinuing",
                "Coronary events (eg, angina, MI, cardiac arrest, and/or sudden death) reported in clinical trials; apomorphine reduces resting systolic and diastolic BP and may have the potential to exacerbate ischemia",
                "Dose-related QT prolongation observed with therapeutic doses of SC apomorphine; although the extent of systemic exposure and peak plasma concentration of apomorphine are lower following the maximum recommended SL dose (30 mg) than following the maximum recommended dose of SC apomorphine (6 mg), QTc prolongation cannot be excluded with SL administration",
                "Withdrawal-emergent hyperpyrexia and confusion reported",
                "Cases of retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, and cardiac valvulopathy have been reported in some patients treated with ergot-derived dopaminergic agents; these complications are thought to be associated with ergoline structure dopamine agonists, whether other nonergot derived dopamine agonists (eg, apomorphine) can cause these reactions is unknown",
                "Hypersensitivity/allergic reactions characterized by urticaria, rash, pruritus, and/or various manifestations of angioedema may occur with SL or SC dosing; SC has sulfite excipient; sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people",
                "Rare incidences of priapism reported during clinical trials",
                "Retinal atrophy detected at all SC doses in albino rat; retinal atrophy/degeneration has been observed in albino rats treated with other dopamine agonists for prolonged periods (~2 years)",
                " "
            ],
            "specific": [
                {
                    "type": "Hemolytic anemia",
                    "description": [
                        "Hemolytic anemia requiring hospitalization reported in the postmarketing setting; many of reported cases included positive direct antiglobulin test (Coombs test), suggesting a potential immune-mediated hemolysis",
                        "Severe anemia, angina, and dyspnea have occurred with hemolytic anemia; some patients were treated with high dose glucocorticoids or blood transfusions",
                        "Hemolytic anemia can appear at any time after apomorphine treatment; if a patient develops anemia while receiving therapy, consider a workup for hemolytic anemia; if hemolytic anemia occurs, consider discontinuing treatment"
                    ]
                },
                {
                    "type": "Drug interaction oveview ",
                    "description": [
                        "5HT3 Antagonists",
                        "Contraindicated with 5HT3 antagonists (eg, ondansetron, granisetron, dolasetron, palonosetron)",
                        "Profound hypotension and loss of consciousness observed when SC apomorphine was administered with ondansetron",
                        "Antihypertensives and vasodilators",
                        "Coadministration may decrease blood pressure",
                        "In a study of SC apomorphine coadministered with SL nitroglycerin, a greater decrease in blood pressure was observed than apomorphine alone",
                        "Advise patients to lie down before and after taking SL nitroglycerin",
                        "Alcohol",
                        "Avoid drinking alcohol after taking apomorphine",
                        "Coadministration may decrease blood pressure",
                        "Dopamine antagonists",
                        "Dopamine antagonists such as neuroleptics (eg, phenothiazine, butyrophenones, thioxantenes) or metoclopramide may diminish the effect of apomorphine (a dopamine agonist)",
                        "QT prolonging drugs",
                        "Caution of coadministered with other drugs that prolong QT interval"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "alosetron",
            "description": {
                "common": "apomorphine, alosetron. Mechanism: unspecified interaction mechanism. Contraindicated. Profound hypotension and loss of consciousness reported when 5HT3 antagonists are coadministered with apomorphine. ."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cisapride",
            "description": {
                "common": "apomorphine and cisapride both increase  QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dolasetron",
            "description": {
                "common": "apomorphine, dolasetron. Mechanism: unspecified interaction mechanism. Contraindicated. Profound hypotension and loss of consciousness reported when 5HT3 antagonists are coadministered with apomorphine. Additionally, dolasetron may cause additive QT prolongation with apomorphine."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dronedarone",
            "description": {
                "common": "apomorphine and dronedarone both increase  QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "granisetron",
            "description": {
                "common": "apomorphine, granisetron. Mechanism: unspecified interaction mechanism. Contraindicated. Profound hypotension and loss of consciousness reported when 5HT3 antagonists are coadministered with apomorphine. ."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "netupitant/palonosetron, apomorphine. Mechanism: unspecified interaction mechanism. Contraindicated. Profound hypotension and loss of consciousness reported when 5HT3 antagonists are coadministered with apomorphine. ."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ondansetron",
            "description": {
                "common": "apomorphine, ondansetron. Mechanism: unspecified interaction mechanism. Contraindicated. Profound hypotension and loss of consciousness reported when 5HT3 antagonists are coadministered with apomorphine. Additionally, ondansetron may cause additive QT prolongation with apomorphine."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "palonosetron",
            "description": {
                "common": "apomorphine, palonosetron. Mechanism: unspecified interaction mechanism. Contraindicated. Profound hypotension and loss of consciousness reported when 5HT3 antagonists are coadministered with apomorphine. ."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "thioridazine",
            "description": {
                "common": "apomorphine and thioridazine both increase  QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adagrasib",
            "description": {
                "common": "adagrasib, apomorphine.\nEither increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amiodarone",
            "description": {
                "common": "apomorphine and amiodarone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride, apomorphine.\nEither decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anagrelide",
            "description": {
                "common": "apomorphine and anagrelide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "arsenic trioxide",
            "description": {
                "common": "apomorphine and arsenic trioxide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether",
            "description": {
                "common": "artemether and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "apomorphine and artemether/lumefantrine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine",
            "description": {
                "common": "apomorphine and asenapine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "apomorphine and buprenorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "buprenorphine subdermal implant and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "buprenorphine transdermal and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "buprenorphine, long-acting injection and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium/magnesium/potassium/sodium oxybates",
            "description": {
                "common": "apomorphine, calcium/magnesium/potassium/sodium oxybates.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "apomorphine and clarithromycin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "disopyramide",
            "description": {
                "common": "apomorphine and disopyramide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dofetilide",
            "description": {
                "common": "dofetilide increases toxicity of apomorphine by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "droperidol",
            "description": {
                "common": "droperidol decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "apomorphine and encorafenib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "apomorphine and entrectinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "eribulin",
            "description": {
                "common": "apomorphine and eribulin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fedratinib",
            "description": {
                "common": "apomorphine will increase the level or effect of fedratinib by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "foscarnet",
            "description": {
                "common": "apomorphine and foscarnet both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glasdegib",
            "description": {
                "common": "apomorphine and glasdegib both increase  QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "granisetron",
            "description": {
                "common": "apomorphine and granisetron both increase  QTc interval. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibutilide",
            "description": {
                "common": "apomorphine and ibutilide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "inotuzumab",
            "description": {
                "common": "inotuzumab and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoflurane",
            "description": {
                "common": "isoflurane and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lefamulin",
            "description": {
                "common": "lefamulin and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "apomorphine and levofloxacin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofexidine",
            "description": {
                "common": "apomorphine and lofexidine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "apomorphine and lopinavir both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine",
            "description": {
                "common": "loxapine decreases effects of apomorphine by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled decreases effects of apomorphine by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "macimorelin and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "maprotiline",
            "description": {
                "common": "apomorphine and maprotiline both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mefloquine",
            "description": {
                "common": "apomorphine and mefloquine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methadone",
            "description": {
                "common": "apomorphine and methadone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "apomorphine, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midostaurin",
            "description": {
                "common": "apomorphine and midostaurin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "apomorphine and mirtazapine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "apomorphine and moxifloxacin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nilotinib",
            "description": {
                "common": "apomorphine and nilotinib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "octreotide",
            "description": {
                "common": "apomorphine and octreotide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "apomorphine and ofloxacin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "apomorphine and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "apomorphine and oxaliplatin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paliperidone",
            "description": {
                "common": "paliperidone decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "panobinostat",
            "description": {
                "common": "apomorphine and panobinostat both increase  QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pazopanib",
            "description": {
                "common": "apomorphine and pazopanib both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentamidine",
            "description": {
                "common": "apomorphine and pentamidine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "apomorphine and pimavanserin both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "pimozide decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pitolisant",
            "description": {
                "common": "apomorphine and pitolisant both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "apomorphine and ponesimod both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "procainamide",
            "description": {
                "common": "apomorphine and procainamide both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "prochlorperazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "promethazine",
            "description": {
                "common": "promethazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propafenone",
            "description": {
                "common": "apomorphine and propafenone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "protriptyline",
            "description": {
                "common": "apomorphine and protriptyline both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinidine",
            "description": {
                "common": "apomorphine and quinidine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib increases toxicity of apomorphine by QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir, apomorphine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased risk of QT prolongation and cardiac arrhythmias."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selinexor",
            "description": {
                "common": "selinexor, apomorphine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "apomorphine and sevoflurane both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "apomorphine and siponimod both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium oxybate",
            "description": {
                "common": "apomorphine, sodium oxybate.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotalol",
            "description": {
                "common": "apomorphine and sotalol both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tetrabenazine",
            "description": {
                "common": "apomorphine and tetrabenazine both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thiothixene",
            "description": {
                "common": "thiothixene decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "toremifene",
            "description": {
                "common": "apomorphine and toremifene both increase  QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing  QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trazodone",
            "description": {
                "common": "apomorphine and trazodone both increase  QTc interval. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "trifluoperazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "apomorphine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vandetanib",
            "description": {
                "common": "apomorphine, vandetanib.\nEither increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval;  if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "vemurafenib and apomorphine both increase  QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that  prolong QT interval is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "apomorphine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "ziprasidone decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "albuterol and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "alfentanil and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "apomorphine and alfuzosin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "alprazolam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, apomorphine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "apomorphine and arformoterol both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atomoxetine",
            "description": {
                "common": "atomoxetine and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azelastine",
            "description": {
                "common": "azelastine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azithromycin",
            "description": {
                "common": "azithromycin increases toxicity of apomorphine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "baclofen",
            "description": {
                "common": "baclofen and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "apomorphine and bedaquiline both increase  QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "belladonna and opium and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "apomorphine, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increases risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "apomorphine and bromocriptine both increase  dopaminergic effects. Use Caution/Monitor. Combination may enhance  efficacy. Monitor for hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brompheniramine",
            "description": {
                "common": "brompheniramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "buprenorphine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "buprenorphine buccal and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butorphanol",
            "description": {
                "common": "butorphanol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabergoline",
            "description": {
                "common": "apomorphine and cabergoline both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "captopril",
            "description": {
                "common": "apomorphine, captopril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbinoxamine",
            "description": {
                "common": "carbinoxamine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carisoprodol",
            "description": {
                "common": "carisoprodol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate, apomorphine.\nEither increases effects of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloral hydrate",
            "description": {
                "common": "chloral hydrate and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "chlordiazepoxide and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine increases toxicity of apomorphine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpheniramine",
            "description": {
                "common": "chlorpheniramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorzoxazone",
            "description": {
                "common": "chlorzoxazone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "apomorphine and citalopram both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clemastine",
            "description": {
                "common": "clemastine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "apomorphine, clobazam. Other (see comment). Use Caution/Monitor. \nComment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "clonazepam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "clorazepate and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "codeine",
            "description": {
                "common": "codeine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "crizotinib and apomorphine both increase  QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclizine",
            "description": {
                "common": "cyclizine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclobenzaprine",
            "description": {
                "common": "cyclobenzaprine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "cyproheptadine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dantrolene",
            "description": {
                "common": "dantrolene and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "apomorphine and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "apomorphine and dasatinib both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "degarelix",
            "description": {
                "common": "apomorphine and degarelix both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "apomorphine and deutetrabenazine both increase  QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexchlorpheniramine",
            "description": {
                "common": "dexchlorpheniramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmedetomidine",
            "description": {
                "common": "dexmedetomidine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "diazepam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difenoxin hcl",
            "description": {
                "common": "difenoxin hcl and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "dimenhydrinate and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "diphenhydramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenoxylate hcl",
            "description": {
                "common": "diphenoxylate hcl and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "donepezil",
            "description": {
                "common": "donepezil and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxylamine",
            "description": {
                "common": "doxylamine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "droperidol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "apomorphine and eliglustat both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "apomorphine and erythromycin base both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "apomorphine and erythromycin ethylsuccinate both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "apomorphine and erythromycin lactobionate both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "apomorphine and erythromycin stearate both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram increases toxicity of apomorphine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estazolam",
            "description": {
                "common": "estazolam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethanol",
            "description": {
                "common": "apomorphine and ethanol both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etomidate",
            "description": {
                "common": "etomidate and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ezogabine",
            "description": {
                "common": "ezogabine, apomorphine.\nEither increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "apomorphine and fluconazole both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "apomorphine and fluoxetine both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurazepam",
            "description": {
                "common": "flurazepam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "apomorphine and formoterol both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "apomorphine and fostemsavir both increase  QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "apomorphine and gemifloxacin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemtuzumab",
            "description": {
                "common": "apomorphine and gemtuzumab both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gilteritinib",
            "description": {
                "common": "apomorphine and gilteritinib both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "goserelin",
            "description": {
                "common": "goserelin increases toxicity of apomorphine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "histrelin",
            "description": {
                "common": "histrelin increases toxicity of apomorphine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "hydromorphone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "hydroxyzine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indacaterol, inhaled",
            "description": {
                "common": "indacaterol, inhaled, apomorphine. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "apomorphine and indapamide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "apomorphine and isradipine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "apomorphine and itraconazole both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketamine",
            "description": {
                "common": "ketamine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketotifen, ophthalmic",
            "description": {
                "common": "apomorphine and ketotifen, ophthalmic both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "apomorphine and lapatinib both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenvatinib",
            "description": {
                "common": "apomorphine and lenvatinib both increase  QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leuprolide",
            "description": {
                "common": "leuprolide increases toxicity of apomorphine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "apomorphine and levalbuterol both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "apomorphine and levodopa both increase  dopaminergic effects. Use Caution/Monitor. Combination may enhance  efficacy. Monitor for hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levorphanol",
            "description": {
                "common": "levorphanol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lithium",
            "description": {
                "common": "apomorphine and lithium both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loperamide",
            "description": {
                "common": "apomorphine and loperamide both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "lorazepam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "loxapine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone decreases effects of apomorphine by pharmacodynamic antagonism. Use Caution/Monitor. Antipsychotics may diminish  the therapeutic effect of anti-parkinson's agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc, apomorphine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "apomorphine and marijuana both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melatonin",
            "description": {
                "common": "apomorphine and melatonin both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meperidine",
            "description": {
                "common": "meperidine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meprobamate",
            "description": {
                "common": "apomorphine and meprobamate both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaxalone",
            "description": {
                "common": "metaxalone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "methadone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methocarbamol",
            "description": {
                "common": "methocarbamol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyldopa",
            "description": {
                "common": "apomorphine and methyldopa both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "apomorphine, methylphenidate.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive CNS stimulation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "metoclopramide decreases levels of apomorphine by pharmacodynamic antagonism. Use Caution/Monitor. Avoid combination if possible."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "midazolam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "midazolam intranasal, apomorphine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone, apomorphine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "apomorphine and mirtazapine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "morphine",
            "description": {
                "common": "morphine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "motherwort",
            "description": {
                "common": "apomorphine and motherwort both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabilone",
            "description": {
                "common": "apomorphine and nabilone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "nalbuphine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olodaterol inhaled",
            "description": {
                "common": "apomorphine and olodaterol inhaled both increase  QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "opium tincture",
            "description": {
                "common": "opium tincture and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "orphenadrine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "osilodrostat and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osimertinib",
            "description": {
                "common": "osimertinib and apomorphine both increase  QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxazepam",
            "description": {
                "common": "oxazepam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "oxycodone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "oxymorphone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod and apomorphine both increase  QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "paliperidone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "papaverine",
            "description": {
                "common": "apomorphine and papaverine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pasireotide",
            "description": {
                "common": "apomorphine and pasireotide both increase  QTc interval. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentazocine",
            "description": {
                "common": "pentazocine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine PO",
            "description": {
                "common": "apomorphine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pramipexole",
            "description": {
                "common": "apomorphine and pramipexole both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primaquine",
            "description": {
                "common": "apomorphine and primaquine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "prochlorperazine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "promethazine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propofol",
            "description": {
                "common": "propofol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quazepam",
            "description": {
                "common": "quazepam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "apomorphine and quinine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ramelteon",
            "description": {
                "common": "apomorphine and ramelteon both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "apomorphine and ranolazine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "rilpivirine increases toxicity of apomorphine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "romidepsin",
            "description": {
                "common": "apomorphine and romidepsin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropinirole",
            "description": {
                "common": "apomorphine and ropinirole both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "scullcap",
            "description": {
                "common": "apomorphine and scullcap both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selpercatinib",
            "description": {
                "common": "selpercatinib increases toxicity of apomorphine by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "apomorphine and sertraline both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "shepherd's purse",
            "description": {
                "common": "apomorphine and shepherd's purse both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "apomorphine and solifenacin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solriamfetol",
            "description": {
                "common": "apomorphine and solriamfetol both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sorafenib",
            "description": {
                "common": "sorafenib and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, apomorphine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil",
            "description": {
                "common": "sufentanil and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sunitinib",
            "description": {
                "common": "apomorphine and sunitinib both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "apomorphine and tacrolimus both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tapentadol",
            "description": {
                "common": "tapentadol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telavancin",
            "description": {
                "common": "apomorphine and telavancin both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temazepam",
            "description": {
                "common": "temazepam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "thiothixene and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "apomorphine and topiramate both increase  sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "tramadol and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "triazolam and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triclabendazole",
            "description": {
                "common": "apomorphine and triclabendazole both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "trifluoperazine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine and apomorphine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triptorelin",
            "description": {
                "common": "triptorelin increases toxicity of apomorphine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "valbenazine and apomorphine both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vardenafil",
            "description": {
                "common": "apomorphine and vardenafil both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, apomorphine.\nEither increases effects of the other by QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "apomorphine and voriconazole both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vorinostat",
            "description": {
                "common": "apomorphine and vorinostat both increase  QTc interval. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziconotide",
            "description": {
                "common": "apomorphine and ziconotide both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of apomorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of apomorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of apomorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eucalyptus",
            "description": {
                "common": "apomorphine and eucalyptus both increase  sedation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flecainide",
            "description": {
                "common": "apomorphine and flecainide both increase  QTc interval. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of apomorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "apomorphine will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sage",
            "description": {
                "common": "apomorphine and sage both increase  sedation. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trimethobenzamide",
            "description": {
                "common": "trimethobenzamide decreases effects of apomorphine by pharmacodynamic antagonism. Minor/Significance Unknown. Trimethobenzamide may decrease the emetic response to apomorphine; monitor for additive CNS effects."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Yawning",
            "percent": "40"
        },
        {
            "name": "Dyskinesia",
            "percent": "35"
        },
        {
            "name": "Drowsiness or somnolence",
            "percent": "35"
        },
        {
            "name": "Nausea or vomiting",
            "percent": "30"
        },
        {
            "name": "Injection site reaction",
            "percent": "26"
        },
        {
            "name": "Dizziness or postural hypotension",
            "percent": "20"
        },
        {
            "name": "Rhinorrhea",
            "percent": "20"
        },
        {
            "name": "Bruising",
            "percent": "16"
        },
        {
            "name": "Chest pain",
            "percent": "15"
        },
        {
            "name": "pressure",
            "percent": "21-28"
        },
        {
            "name": "angina",
            "percent": "1-15"
        },
        {
            "name": "Nausea",
            "percent": "11-13"
        },
        {
            "name": "Oral",
            "percent": "2-13"
        },
        {
            "name": "pharyngeal soft tissue swelling",
            "percent": "9-11"
        },
        {
            "name": "Somnolence",
            "percent": "10"
        },
        {
            "name": "Oral",
            "percent": "10"
        },
        {
            "name": "pharyngeal soft tissue pain and paresthesia",
            "percent": "4"
        },
        {
            "name": "Dizziness",
            "percent": "2"
        },
        {
            "name": "Hallucination or confusion",
            "percent": "6-8"
        },
        {
            "name": "Edema",
            "percent": "6-7"
        },
        {
            "name": "swelling of extremities",
            "percent": "4-7"
        },
        {
            "name": "Granuloma",
            "percent": "4-7"
        },
        {
            "name": "Pruritus",
            "percent": "3-7"
        },
        {
            "name": "Headache",
            "percent": "2-7"
        },
        {
            "name": "Rhinorrhea",
            "percent": "6"
        },
        {
            "name": "Oral mucosal erythema",
            "percent": "4-6"
        },
        {
            "name": "Vomiting",
            "percent": "4-6"
        },
        {
            "name": "Fatigue",
            "percent": "1-6"
        },
        {
            "name": "Oral ulceration and stomatitis",
            "percent": "1-6"
        },
        {
            "name": "Hypersensitivity",
            "percent": "2-4"
        },
        {
            "name": "Fall",
            "percent": null
        },
        {
            "name": "Hyperhidrosis",
            "percent": null
        },
        {
            "name": "Dry mouth",
            "percent": null
        },
        {
            "name": "Laceration",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "hypotension",
            "percent": null
        }
    ]
}